Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in France / NCT07260942
Recruiting Not applicable

Ferroptosis Role in the Pathophysiology of Systemic Lupus Erythematosus

NCT07260942 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Bordeaux
Phase
Not applicable
Started
2026-04-21
Last updated
2026-05-18

Condition(s) studied

Systemic Lupus Erythematosus

Investigational drug(s) / intervention(s)

blood sample →

blood sample: 30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation

Study summary

The study aims at defining the role of ferroptosis s in the physiopathology of systemic lupus erythematosus (SLE). Ferroptosis (phenomenon of cellular death regulated by iron) is a metabolic pathway potentially implicated in SLE with potential for the discovery of new therapeutic strategies.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age ≥ 18 years; * diagnosis of systemic lupus erythematosus; * being affiliated to health insurance, willing to participate and to sign informed consent; * control group : patients with a diagnosis of rheumatoid arthritis or an inflammatory bowel disease. Exclusion Criteria: * pregnant or breastfeeding women; * patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).

Primary outcome measure(s)

  • Measurement of lipid peroxidation in regulatory T lymphocytes population in lupus subjects. — At baseline (Day 0)

Trial sites (1)

FacilityCityRegionStatus
CHU de Bordeaux - service de rhumatologie Bordeaux France Recruiting

More University Hospital, Bordeaux trials in France

Prostaglandins Versus Trans-cervical Balloon for Induction of Labor in Fetal Growth Restriction (PROBIN) Recruiting
A Study to Better Understand the Biological and Molecular Mechanisms Involved in Glioblastoma Recurrence and Progression Recruiting
Parkinsonism-Related Oscillations in the Cortico-Basal Ganglia-Thalamic Network During Movement: Beyond the Frequency Range Recruiting
Comparison of Functional Outcomes of Ejaculation-preserving Partial Trans Urethral Resection of the Prostate With Complete Trans Urethral Resection of the Prostate for Benign Prostatic Obstruction Recruiting
Performance of Lung MRI Combined to Synthetic CT in the Follow-up of Lung Nodules Recruiting

Other trials for the same condition

A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus Active, not recruiting
HLA Antibodies in Systemic Lupus Erythematosus Recruiting
Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2) Active, not recruiting
Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU Recruiting
Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07260942 on ClinicalTrials.gov ↗ ← All trials in France